Assessment of Serum Levels of Janus Kinase 1 and 2 in Patients With Cholinergic Urticaria

Status: Recruiting
Location: See location...
Intervention Type: Diagnostic test
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Cholinergic Urticaria (CholU) is as a subtype of CIndU caused by an increase in the core body temperature, such as to activate the sweating reflex. It can occur in response to physical exercise, hot bathing and/or emotional stress. Clinically it appears as pinpointing and highly pruritic wheals with surrounding erythema, CholU can be accompanied by severe symptoms such as angioedema, respiratory symptoms or anaphylaxi CholU is frequently associated with atopic dermatitis (AD) The JAK-STAT is a mast cell (MC) signaling pathway activated downstream of IgE and IL-3 with important roles in MC homeostasis via regulation of proliferation, survival, and release of mediators. JAK-STAT activation is associated with polarization toward Th2, B cell isotype switching to IgE production, and IgE-dependent degranulation and cytokine release . Because both IL-4 and IL-13 use the IL-4Rα as a receptor component, these cytokines activate any common signaling pathways. Both of these cytokines use Janus kinases (JAKs) to initiate signaling and activate signal transducer and activator of transcription-6 (STAT6), which is a transcription factor required for many of their biologic functions. The non-receptor protein tyrosine kinases JAK1 and JAK3 associate with the IL-4Rα and γC, respectively. The binding of IL-4 to its receptor induces the transphosphorylation of JAK1 and JAK3, an event that activates these kinases and thereby initiates the early events of signal transduction .

Eligibility
Participation Requirements
Sex: All
Minimum Age: 15
Maximum Age: 55
Healthy Volunteers: f
View:

• The study will include 45 adult patients complaining of CholU as well as 45 healthy controls.

Locations
Other Locations
Egypt
Sohag university Hospital
RECRUITING
Sohag
Time Frame
Start Date: 2023-12-15
Estimated Completion Date: 2024-12-10
Participants
Target number of participants: 90
Treatments
Active_comparator: cases group
group of cases with cholinergic urticaria
Active_comparator: control group
control group not have cholinergic urticaria
Related Therapeutic Areas
Sponsors
Leads: Sohag University

This content was sourced from clinicaltrials.gov